MedTrace Logo

Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR)

NCT06328101 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-03-25

No results posted yet for this study

Summary

The goal of this observational, retrospective study is to learn about cancer risk in autoimmune pancreatitis (AIP) patients. The main questions it aims to answer are:

* Do patients with AIP have higher incidence of cancer in comparison to general population?
* What is the overall prevalence of cancer in AIP patients?
* What are the characteristics of AIP patients associated with the incidence of cancer?

Conditions

  • Autoimmune Pancreatitis Type 1
  • Autoimmune Pancreatitis Type 2

Sponsors & Collaborators

  • University Medical Centre Maribor

    collaborator OTHER

  • Aalborg University Hospital

    collaborator OTHER

  • University Hospital Munich

    collaborator OTHER

  • Tartu University Hospital

    collaborator OTHER

  • University Hospital in Halle

    collaborator OTHER

  • University Medical Center Goettingen

    lead OTHER

Principal Investigators

  • Cecilie Siggaard Knoph, MD · Univesity Hospital Alborg

  • Julian Cardinal von Widdern, MD · University Hospital Halle (Saale)

  • Karri Kasse, MD · Tartu University Hospital

  • Ivonne Regel, PhD · University Hospital of Munich (LMU)

  • Jonas Rosendahl, MD, PhD · University Hospital Halle (Saale)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-09-01
Completion
2025-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06328101 on ClinicalTrials.gov